SELLAS Life Sciences Says Three Abstracts Evaluating SLS009, Potent, Selective CDK9 Inhibitor, In Preclinical Models Of PDAC Accepted For Poster Presentation At AACR Conference On Pancreatic Cancer

-  Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – 
 

-  Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health -
 

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that three abstracts evaluating SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, in preclinical models of pancreatic ductal adenocarcinoma (PDAC) have been accepted for poster presentation at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development. The conference will be held September 25–28, 2026, at the Hilton San Diego Bayfront in San Diego, CA.